Aman Chauhan (@amanchauhanmd) 's Twitter Profile
Aman Chauhan

@amanchauhanmd

#Oncologist, #Neuroendocrine #NETS Tumor Specialist, #SCLC #LCNEC #Phase I/II #clinicaltrial #drugdevelopment #Theranostics @SylvesterCancer Tweets are my own

ID: 1008176501303504896

calendar_today17-06-2018 02:36:23

1,1K Tweet

2,2K Takipçi

966 Takip Edilen

Aman Chauhan (@amanchauhanmd) 's Twitter Profile Photo

Let's talk neuroendocrine oncology and Radiopharmaceuticals over a cup of coffee in beautiful Chicago. See ya soon And don't forget to checkout our #ASCO25 abstracts #DAREONTM-9, a phase Ib study of obrixtamig plus topotecan in patients (pts) with advanced small cell lung

Rachel Riechelmann (@rachelriechelm2) 's Twitter Profile Photo

I am very honored to be nominated for Director of Membership of ESMO - Eur. Oncology Election. 😊 the President’s call: #ESMOMembers vote for leaders who’ll shape ESMO’s future. Vote for Directors of Education, Public Policy & Membership , and Chair and members of the Nomination Committee

I am very honored to be nominated for Director of Membership of <a href="/myESMO/">ESMO - Eur. Oncology</a> Election. 😊

the President’s call: 
 #ESMOMembers vote for leaders who’ll shape ESMO’s future. Vote for Directors of Education, Public Policy &amp; Membership , and Chair and members of the Nomination Committee
Aman Chauhan (@amanchauhanmd) 's Twitter Profile Photo

What a day! We consented two patients to our SVV-Ipi-Nivo study (NCT06889493) for high-grade neuroendocrine cancer—closing Cohort 1 in under a month! To add to the momentum, we received incredible news of a generous philanthropic gift from the Nichole Borchard Foundation to

What a day! We consented two patients to our SVV-Ipi-Nivo study (NCT06889493) for high-grade neuroendocrine cancer—closing Cohort 1 in under a month! To add to the momentum, we received incredible news of a generous philanthropic gift from the Nichole Borchard Foundation to
gilberto lopes (@glopesmd) 's Twitter Profile Photo

Have you signed up for #MiamiNights yet? Sylvester Comprehensive Cancer Center @asco #asco25 We are hiring - Looking for chiefs for breast and head and neck and oncologists in pretty much all areas DM me @glopesmd

Aman Chauhan (@amanchauhanmd) 's Twitter Profile Photo

Doctors from across continents and dedicated patient advocates reconnecting at #ASCO25 — a true reflection of the global spirit of ASCO.

Doctors from across continents and dedicated patient advocates reconnecting at #ASCO25 — a true reflection of the global spirit of <a href="/ASCO/">ASCO</a>.
Samantha El Warrak (@samanthawarrak) 's Twitter Profile Photo

Just arrived in Chicago! 🌆 Excited to present on trends in breast cancer mortality & contributing risk factors ASCO 🗓️ Join me TOMORROW Saturday 5/31 at my poster session: 🕜 1:30 PM – 4:30 PM 📍 Hall A, Poster Board 327 Can’t wait to connect! #ASCO25 #BreastCancer

Just arrived in Chicago! 🌆 Excited to present on trends in breast cancer mortality &amp; contributing risk factors <a href="/ASCO/">ASCO</a> 

🗓️ Join me TOMORROW Saturday 5/31 at my poster session:
🕜 1:30 PM – 4:30 PM
📍 Hall A, Poster Board 327

Can’t wait to connect! #ASCO25 #BreastCancer
Sylvester Comprehensive Cancer Center (@sylvestercancer) 's Twitter Profile Photo

Thank you to everyone who joined us at our Miami Nights reception during the 2025 American Society of Clinical Oncology Annual Meeting in #Chicago! It was an unforgettable evening where we celebrated oncology professionals who are shaping the future of cancer care. #ASCO25

Anwaar Saeed (@anwaarsaeed3) 's Twitter Profile Photo

😇 Honored to lead & present topline Ph 2 data for DSP107 +/- Atezolizumab in 3L MSS CRC #ASCO25: 🔹 Median OS: 17 months >> 60% improvement over SOC. 🔹 ~80% with liver metastases—the most challenging subset. 🔜 a randomized Phase 2b trial to advance this promising approach ✨

😇 Honored to lead &amp; present topline Ph 2 data for DSP107 +/- Atezolizumab in 3L MSS CRC #ASCO25:
🔹 Median OS: 17 months &gt;&gt; 60% improvement over SOC. 
🔹 ~80% with liver metastases—the most challenging subset. 
🔜 a randomized Phase 2b trial to advance this promising approach ✨
Aman Chauhan (@amanchauhanmd) 's Twitter Profile Photo

Kicked off my first day at the new Sylvester Griffin Cancer Research Building by enrolling a patient in Dr. Soares’s Adjuvant CAPTEM study for pNETs during clinic—excited to hit the ground running! Sylvester Comprehensive Cancer Center Heloisa Soares MD

Kicked off my first day at the new Sylvester Griffin Cancer Research Building by enrolling a patient in Dr. Soares’s Adjuvant CAPTEM study for pNETs during clinic—excited to hit the ground running!

<a href="/SylvesterCancer/">Sylvester Comprehensive Cancer Center</a> <a href="/helops79/">Heloisa Soares MD</a>
gilberto lopes (@glopesmd) 's Twitter Profile Photo

Alright! It’s Friday after ASCO and I finally have time to tweet again :) Full #ASCO25 Symplur report for most influential tweeters. Thank you for following all of us and for being part of the family! And especially for amplifying messages that will help improve care for

Alright! It’s Friday after <a href="/ASCO/">ASCO</a> and I finally have time to tweet again :) 

Full #ASCO25 <a href="/symplur/">Symplur</a> report for most influential tweeters. 

Thank you for following all of us and for being part of the family! And especially for amplifying messages that will help improve care for
Aman Chauhan (@amanchauhanmd) 's Twitter Profile Photo

Just yesterday, I was consulted on two newly diagnosed cases of gastric NEC—one localized, one advanced. I know, incredibly rare! A timely reminder that NETs and NECs are worlds apart and demand fundamentally different diagnostic workups and treatment strategies. The silver

Just yesterday, I was consulted on two newly diagnosed cases of gastric NEC—one localized, one advanced. I know, incredibly rare! A timely reminder that NETs and NECs are worlds apart and demand fundamentally different diagnostic workups and treatment strategies.

The silver
Aman Chauhan (@amanchauhanmd) 's Twitter Profile Photo

Had a great time discussing the latest advances in high-grade neuroendocrine carcinoma with my amazing NANETS colleagues on the #NETCAST podcast. 🎙️ Promising Advances in NEC Research and Treatment Tune in here: art19.com/shows/netcast/… #NeuroendocrineCancer #NEC #NANETS

Neuroendocrine Cancer Foundation (@ncfcancer) 's Twitter Profile Photo

It is with deep sadness that we share the passing of Dr. Richard R.P. Warner, who left us on June 15, 2025 in Denver, Colorado at the age of 97. A visionary physician and researcher, Dr. Warner founded the Carcinoid Cancer Foundation in 1968. His tireless work has touched

It is with deep sadness that we share the passing of Dr. Richard R.P. Warner, who left us on June 15, 2025 in Denver, Colorado at the age of 97. A visionary physician and researcher, Dr. Warner founded the Carcinoid Cancer Foundation in 1968. His tireless work has touched
Aman Chauhan (@amanchauhanmd) 's Twitter Profile Photo

Grateful to the Phase 1 Team at Ohio State University for the opportunity to present on hPG80, a promising new blood-based biomarker. We’re excited to validate its role in disease monitoring through ETCTN 10588—a multicenter randomized study now nearing completion. Later, I had

Grateful to the Phase 1 Team at Ohio State University for the opportunity to present on hPG80, a promising new blood-based biomarker. We’re excited to validate its role in disease monitoring through ETCTN 10588—a multicenter randomized study now nearing completion.

Later, I had